Prostatype Genomics AB (OSTO:PROGEN) Cash And Cash Equivalents : kr11.70 Mil (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB Cash And Cash Equivalents?

Prostatype Genomics AB's quarterly cash and cash equivalents declined from Dec. 2022 (kr4.81 Mil) to Mar. 2023 (kr0.24 Mil) but then increased from Mar. 2023 (kr0.24 Mil) to Jun. 2023 (kr11.70 Mil).

Prostatype Genomics AB's annual cash and cash equivalents declined from Dec. 2021 (kr9.83 Mil) to Dec. 2022 (kr4.81 Mil) and declined from Dec. 2022 (kr4.81 Mil) to Dec. 2023 (kr2.68 Mil).

Prostatype Genomics AB Cash And Cash Equivalents Historical Data

The historical data trend for Prostatype Genomics AB's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB Cash And Cash Equivalents Chart

Prostatype Genomics AB Annual Data

Trend

Jun18

Jun19

Dec21

Dec22

Dec23

Cash And Cash Equivalents

8.21

2.69

9.83

4.81

2.68

Prostatype Genomics AB Quarterly Data
	Jun18	Jun19	Mar20	Jun20	Sep20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial											15.26	4.81	0.24	11.70	2.68

Prostatype Genomics AB Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Prostatype Genomics AB (OSTO:PROGEN) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Prostatype Genomics AB Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Prostatype Genomics AB (OSTO:PROGEN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

PGO:Germany

Address

Gustaf III:s Boulevard 34, Solna, SWE, 169 73

Website

https://www.prostatypegenomics.com

Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (OSTO:PROGEN) Headlines

No Headlines